NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Bruker Corporation
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Bruker BioSpin Group Introduces New Online Platform to Connect NMR Scientists and Advance NMR Research in Europe - Bruker Introduces Connexus: A NMR Capacity Sharing Cloud-based Platform for Collaboration between Scientists and Analytical Labs in Europe - Bruker.com
Bruker BioSpin Group Introduces New Online Platform to Connect NMR Scientists and Advance NMR Research in Europe

 

NewswireToday - /newswire/ - Zürich, Switzerland, 2022/01/26 - Bruker Introduces Connexus: A NMR Capacity Sharing Cloud-based Platform for Collaboration between Scientists and Analytical Labs in Europe - Bruker.com. NASDAQ: BRKR

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Bruker BioSpin announces the introduction of Connexus® in Europe a cloud-based collaboration platform that connects nuclear magnetic resonance (NMR) scientists in need of analytical services and data evaluation expertise with NMR laboratories with available capabilities. By bringing the interested parties together, Connexus offers clients new access to previously inaccessible high-performance NMR technology and tools, while maximizing instrument productivity for laboratories providing analytical services.

By joining the Connexus Platform, academic and industry clients can now benefit from the latest technological advances and scientific instruments. Whether scientists are experiencing long queues at their own instruments or they lack the infrastructure, time, or expertise required for a particular project, they can now select and connect with a suitable provider based on analysis needs, location, and price. Connexus therefore alleviates the technological and capacity constraints that scientists may face and can help clients advance their research and analyses.

Participating laboratories, or service providers, can maximize their instrument uptime by providing analytical services to clients in need, thereby reducing the total cost of ownership (TCO) of an instrument. The additional income generated by joining Connexus provides an opportunity to optimize laboratory tools, processes and infrastructure. Finally, joining the Connexus network opens the door to developing a community of scientists, allowing members to collaborate, gain exposure to cutting-edge research, and advance scientific discoveries.

Connexus is the first commercially available platform of its kind offering a convenient and connected end-to-end workflow, from client requests to sample transport, uploading results and completing payments. Service providers and clients benefit from intra-platform interactions and seamless transactions. All communications and data are fully encrypted in the secure and user-friendly cloud-based software, which can be accessed from any browser without the need for time-consuming installations or updates.

Dr. Falko Busse, President of the Bruker BioSpin group, comments: “Bruker is widely regarded as a leader in analytical Magnetic Resonance instrumentation and tools, products and solutions. To complement our offerings to our customers, we continue to develop our digital capabilities to support the rapidly changing needs of the scientific community, especially in the post-COVID era. Connexus represents an important step in our vision of a digitally conscious total solution provider beyond instruments and a trusted business partner for our customers and the markets we serve.”

The Connexus rollout will initially start with a dedicated introductory program in European countries.

Connexus (bruker.com/connexus) is secured by the RFC 7519 authentication standard, meets the requirements of the FIPS 140-2 security standard and fully complies with the General Data Protection Regulation (GDPR).

About Bruker Corporation

Bruker (bruker.com) is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Bruker Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Bruker BioSpin Group Introduces New Online Platform to Connect NMR Scientists and Advance NMR Research in Europe

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Thorsten Thiel, Ph.D. - Bruker.com 
+49(721) 5161 6500 thorsten.thiel[.]bruker.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Bruker Corporation securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Bruker Corporation / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

DSM and the World Food Programme Partner to Improve Nutrition Around the World
European Commission Approves Cabometyx® as A Second-line Treatment for People Living with Radioactive Iodine-refractory Differentiated Thyroid Cancer
Shionogi and NEC Enter into Strategic Research Collaboration for Novel Hepatitis B Therapeutic Vaccine
Boehringer Ingelheim Selects Veeva Development Cloud Worldwide to Bring Innovative Therapies to Patients Faster
Ipsen Announces Investment in New State-of-the-art Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide)
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets
Veeva Widely Recognized for Leadership and Innovation in Support of Customers and Employees
Veeva Vault CDMS Selected by Idorsia to Modernize Clinical Data Management
Health Canada Approves Ipsen’s Sohonos (Palovarotene Capsules) as the First Approved Treatment for Fibrodysplasia Ossificans Progressiva
LYSARC Partners with Veeva to Accelerate Innovation for Lymphoma Treatments
PharmaEssentia Selects Veeva Data Cloud to Support Launch of Novel Therapy for Rare, Chronic Blood Cancers
Transgene and NEC Announce Positive Preliminary Data from Phase I Studies of TG4050 - A Novel Individualized Neoantigen Cancer Vaccine
DSM Plans New Production Site for Bovaer® in Dalry, Scotland
Celltrion Pharm Selects TrackWise QMS for Scalability and Data Integrity
Ipsen Adds Another Program into its Pre-clinical R&D Oncology Pipeline through An Exclusive Worldwide Collaboration with Accent Therapeutics

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2022 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)